Previously, we demonstrated that sog9 cells, a murine L cell mutant, are deficient in the expression of C4ST (chondroitin 4-O-sulfotransferase)-1 and that they synthesize fewer and shorter CS (chondroitin sulfate) chains. These results suggested that C4ST-1 regulates not only 4-O-sulfation of CS, but also the length and amount of CS chains; however, the mechanism remains unclear. In the present study, we have demonstrated that C4ST-1 regulates the chain length and amount of CS in co-operation with ChGn-2 (chondroitin N-acetylgalactosaminyltransferase 2). Overexpression of ChGn-2 increased the length and amount of CS chains in L cells, but not in sog9 mutant cells. Knockdown of ChGn-2 resulted in a decrease in the amount of CS in L cells in a manner proportional to ChGn-2 expression levels, whereas the introduction of mutated C4ST-1 or ChGn-2 lacking enzyme activity failed to increase the amount of CS. Furthermore, the non-reducing terminal 4-O-sulfation of N-acetylgalactosamine residues facilitated the elongation of CS chains by chondroitin polymerase consisting of chondroitin synthase-1 and chondroitin-polymerizing factor. Overall, these results suggest that the chain length of CS is regulated by C4ST-1 and ChGn-2 and that the enzymatic activities of these proteins play a critical role in CS elongation.
- chondroitin sulfate
CS (chondroitin sulfate) is a class of GAG (glycosaminoglycan) that is widely distributed on the surface of cells and within the extracellular matrix. CS is covalently linked to specific serine residues of core proteins and occurs as CS PGs (proteoglycans). CS moieties vary considerably in the size and number of GAG chains per core protein and in the position and degree of sulfation; therefore these highly variable moieties are able to store a massive amount of information and exert a variety of biological functions [1,2]. CS and characteristic CS chains exert their specific functions in a tissue- and cell-type-specific manner, suggesting that sulfation and polymerization of CS chains are strictly regulated. A previous study suggested that CS elongation is associated with increased binding of atherogenic lipids and atherosclerosis . Moreover, deficiency in SLC35D1 (solute carrier 35D1), which encodes an endoplasmic reticulum nucleotide–sugar transporter, caused shortening of CS chains and led to skeletal dysplasias . Therefore an understanding of the CS chain elongation mechanism is essential for elucidating multiple pathogenic mechanisms.
Multiple glycosyltransferases and sulfotransferases are responsible for the biosynthesis of CS  (Figure 1). The synthesis of the linkage tetrasaccharide sequence, the so-called GAG–protein linkage region (GlcAβ1-3Galβ1-3Galβ1-4Xylβ1-O-Ser), is initiated by the addition of a xylose (Xyl) residue to a specific serine (Ser) residue in the core protein, followed by the sequential transfer of galactose (Gal) residues, and completed by the addition of the glucuronic acid (GlcA) residue . Following completion of the synthesis of the linkage tetrasaccharide sequence, polymerization of repeating disaccharide units occurs by the alternate transfer of GlcA and GalNAc (N-acetylgalactosamine) . Then, a number of sulfotransferases modify the chondroitin backbone with sulfate at positions 4 and 6 of the GalNAc residues and position 2 of the GlcA residues, resulting in structural diversity of CS moieties .
To date, six homologous glycosyltransferases, ChSy (chondroitin synthase)-1, ChSy-2, ChSy-3, ChPF (chondroitinpolymerizing factor), and ChGn (chondroitin N-acetylgalactosamine transferase)-1 and -2, all of which are probably responsible for CS biosynthesis, have been cloned by us and others [7–14]. We have demonstrated chondroitin polymerization with alternating GalNAc and GlcA residues when any two of ChSy-1, ChSy-2, ChSy-3 and ChPF were co-expressed [8–10] (Figure 1). ChGn-1 and -2 are thought to catalyse chain initiation and elongation, exhibiting activities of GalNAcT (β1,4-N-acetylgalactosaminyltransferase)-I and -II [11–14] (Figure 1). In addition, seven sulfotransferases involved in the sulfation of CS have been cloned to date . Four sulfotransferases that catalyse sulfation of position 4 of the GalNAc residue have been cloned. C4ST (chondroitin 4-O-sulfotransferases)-1, -2 and -3 are responsible for the sulfation of position 4 of GalNAc residues in CS, whereas D4ST (dermatan 4-O-sulfotransferase)-1 catalyses the transfer of a sulfate residue to GalNAc residues next to IdoA (iduronic acid) in DS (dermatan sulfate) [15–19] (Figure 1). C6ST-1 (chondroitin 6-O-sulfotransferase-1) transfers sulfate to position 6 of the GalNAc residue [20,21]. Uronyl 2-O-sulfotransferase catalyses the 2-O-sulfation of GlcA and IdoA. GalNAc4S-6ST (N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase) transfers a sulfate residue to position 6 of GalNAc(4S) formed by C4ST  (Figure 1).
Previously, we demonstrated that sog9 mutant cells were deficient in the expression of C4ST-1 and synthesized shorter CS chains with low 4-O-sulfation levels and that overexpression of C4ST-2 or D4ST-1 in sog9 cells did not lead to an increase in the chain length or amount of CS . In addition, C4ST-1-deficient mice showed a 90% decrease in GalNAc(4S) structures and a severe reduction in the amount of CS . These results suggested that C4ST-1 regulates CS 4-O-sulfation, chain length and amount; moreover, other C4ST/D4ST family members, including C4ST-2 and D4ST-1, does not compensate for the loss of C4ST-1. Therefore the 4-O-sulfation of CS chains by C4ST-1 may facilitate the elongation of CS chains; however, the C4ST-1 mechanism remains elusive. We hypothesized that 4-O-sulfation of non-reducing terminal GalNAc formed by ChGn-1 or -2 markedly enhances the elongation of CS chains by chondroitin polymerases. In the present paper, we report that C4ST-1 co-operates with ChGn-2 in CS chain elongation.
UDP-[U-14C]GlcA (285.2 mCi/mmol) and UDP-[3H]GalNAc (10 Ci/mmol) were purchased from NEN Life Science Products. Unlabelled UDP-GlcA and UDP-GalNAc were obtained from Sigma. 35S-labelled PAPS (adenosine 3′-phosphate 5′-phosphosulfate) (1.69 mCi/mmol) was purchased from PerkinElmer Life Sciences. Chondroitin (a chemically desulfated derivative of whale cartilage CS-A), Proteus vulgaris chondroitinase ABC (EC 126.96.36.199), and Arthrobacter aurescens chondroitinase ACII were purchased from Seikagaku. Even-numbered regular chondro-oligosaccharides, (4GlcAβ1-3GalNAcβ1-)2, [4GlcAβ1-3GalNAc(4S)β1-]2 and Oligo-2 (see Table 1), were prepared by hyaluronidase digestion of chondroitin or whale cartilage CS-A followed by gel filtration on a Bio-Gel P-10 column (1.6 cm×95 cm) and HPLC on an amine-bound silica column as described in . Odd-numbered chondro-oligosaccharides, Oligo-1, Oligo-3 and Oligo-4 (see Table 1), were prepared by partially digesting chondroitin with chondroitinase ABC followed by mercuric acetate treatment , and purified by gel filtration on a Bio-Gel P-10 column (1.6 cm×95 cm) followed by HPLC on an amine-bound silica column as described previously . A sulfated pentasaccharide, Oligo-5 (see Table 1), used as an acceptor, was isolated by HPLC after partial chondroitinase ABC digestion of whale cartilage CS-A followed by mercuric acetate treatment. The resulting pentasaccharide was then structurally characterized using enzymatic digestion. A partially sulfated pentasaccharide, Oligo-6 (see Table 1), used as an acceptor, was synthesized by ChGn-2 from [4GlcAβ1-3GalNAc(4S)β1-]2 prepared above. It was purified by HPLC and structurally characterized enzymatically. Superdex™ Peptide HR10/30, Superdex™ Peptide 75 and Superdex™ 200 10/300 GL columns were obtained from GE Healthcare. Mouse L fibroblasts and their mutant derivatives, sog9 cells, were kindly provided by Dr Frank Tufaro (Allera Health Products, St. Petersburg, FL, U.S.A.). Sog9-C4ST-1-1 (high expression) and sog9-C4ST-1-5 (low expression) cells were isolated previously .
Establishment of an expression vector for ChGn-1 and ChGn-2, and preparation of cells that stably express transfected ChGn-1 and ChGn-2
The cDNA fragment encoding ChGn-1 was amplified by RT (reverse transcription) using total RNA from G361 human melanoma cells (A.T.C.C. CRL-1424) as a template and a 5′-primer (5′-CGGGATCCTCTGGACGCATGGCTGATTC-3′) and a 3′-primer (5′-CGGGATCCCATCTCTGACCCATCAGTCC-3′) each containing a BamHI site. The cDNA fragment encoding ChGn-2 was amplified by RT using total RNA from G361 human melanoma cells as a template and a 5′-primer (5′-CGCGGATCCTTGTTAGGCAAATACACATTAATAAG-3′) and a 3′-primer (5′-CGCGGATCCGTTTTGTGGTTCATACAGTAACGC-3′) each containing a BamHI site. PCR was carried out with KOD-Plus DNA polymerase (TOYOBO) for 30 cycles at 94 °C for 30 s, 53 °C for 42 s and 68 °C for 180 s in 5% (v/v) DMSO. The PCR fragments were subcloned into the BamHI site of the pCMV expression vector (Invitrogen). The fidelity of the plasmid constructs (pCMV-ChGn-1 and pCMV-ChGn-2) was confirmed by DNA sequencing. The expression plasmid (6.7 μg) was transfected into L and sog9 cells on 100-mm-diameter plates using FuGENE® 6 (Roche) according to the manufacturer's instructions. Transfectants were cultured in the presence of 300 μg/ml G418. Transfected colonies were picked up and propagated for experiments.
ChGn-2 silencing in L cells was performed using MISSION shRNA (short hairpin RNA) (Sigma). The shRNA plasmid (6.7 μg) was transfected into L cells on 100-mm-diameter plates using FuGENE® 6 according to the manufacturer's instructions. Transfectants were cultured in the presence of 0.4 mg/ml puromycin. Resultant colonies were then picked up and propagated for experiments.
A two-stage PCR mutagenesis method was used to construct separate ChGn-2 and C4ST-1 mutants. Two separate PCRs were performed to generate two overlapping gene fragments using the full-length form of ChGn-2 or C4ST-1 cDNA as a template. In the first PCR, the sense 5′-primer described above and the antisense internal mutagenic primer listed below was used: ChGn-2 D184A 5′-AAATAGATATCAACAGCACAGAAAAACATC-3′ (the mutated nucleotides are underlined and in bold). In the second round of PCR, the sense internal mutagenic primer (complementary to the antisense internal mutagenic primer) and the antisense 3′-primer described above were used. In the case of C4ST-1, the sense 5′-primer (5′-GAAGATCTAGGACAAAGCCATGAAGCCGGC-3′) and the antisense internal mutagenic primer C4ST-1 R586A 5′-CTCGAAGGGTTCCGCCACGAACAGGAA-3′ (the mutated nucleotides are underlined and in bold) were used. In the second round of PCR, the sense internal mutagenic primer (complementary to the antisense internal mutagenic primer) and the antisense 3′-primer (5′-ATAACCCAGTCTCCATAGAATTCTTTTGA-3′) were used. These two PCR products were gel-purified and then used as a template for a third PCR containing the sense 5′-primer and the antisense 3′-primer described above. The final PCR fragment was subcloned into the BamHI site or BamHI/EcoRI site of the pCMV expression vector respectively (Invitrogen). The fidelity of the plasmid constructs (pCMV-ChGn-2 D367A and pCMV-C4ST-1 R186A) was confirmed by DNA sequencing.
Quantitative real-time RT–PCR
Total RNA was extracted from L and sog9 cells using TRIzol® reagent (Invitrogen). The cDNA was synthesized from ~1 μg of total RNA using Moloney murine leukaemia virus reverse transcriptase (Promega) and an oligo(dT)20-M4 adaptor primer (TaKaRa). The primer sequences used were as follows: ChGn-1, forward primer 5′-AGAAGAAATAAATGAAGTCAAAGGAATAC-3′ and reverse primer 5′-GAAGTAGATGTCCACATCACAG-3′; and ChGn-2, forward primer 5′-CCTAGAATCTGTCACCAGT-3′ and reverse primer 5′-GTTAAGGAATTCGGCTGAGAAATA-3′; and GAPDH (glyceraldehyde-3-phosphate dehydrogenase), forward primer 5′-CATCTGAGGGCCCACTG-3′ and reverse primer 5′-GAGGCCATGTAGGCCATGA-3′. Quantitative real-time RT–PCR was performed using a FastStart DNA Master plus SYBR Green I (Roche) in a LightCycler ST300 (Roche). The expression levels of ChGn-1 or ChGn-2 mRNA were normalized to that of the GAPDH transcript.
Derivatization of GAGs from L and sog9 cells using a fluorophore, 2-aminobenzamide
GAGs from L and sog9 cells were prepared as described previously [23,27]. The purified GAG fraction was digested with chondroitinase ABC, and the digests were then derivatized with 2-aminobenzamide and analysed by HPLC as described previously .
Gel-filtration chromatography of GAGs
To determine the chain length of GAGs, the purified GAG fraction was subjected to reductive β-elimination using NaBH4/NaOH, and then analysed by gel-filtration chromatography on a Superdex™ 200 column (10 mm×300 mm) eluted with 0.2 M NH4HCO3 at a flow rate of 0.4 ml/min. Fractions were collected at 3-min intervals, freeze-dried and digested with chondroitinase ABC. The digests were derivatized with 2-aminobenzamide and then analysed by HPLC on an amine-bound PA-03 column .
Polymerization assay and identification of polymerization reaction products
The ChSy-1 and ChPF expression plasmids (3.0 μg each) were co-transfected into COS-1 cells on 100-mm plates using FuGENE® 6 as described previously . At 2 days after transfection, 1 ml of the culture medium was collected and incubated with 10 μl of IgG–Sepharose (GE Healthcare) for 1 h at 4 °C. The beads recovered by centrifugation were washed with, and resuspended in, the assay buffer and then tested for N-acetylgalactosaminyltransferase activity, as described previously . The oligosaccharides used are listed in Table 1. Polymerization reactions using Oligo-1, Oligo-2, Oligo-5 and Oligo-6 as acceptors were co-incubated in reaction mixtures containing the following constituents in a total volume of 20 μl: 1 nmol of Oligo-1, -2, -5 or -6, 0.25 mM UDP-GalNAc, 0.25 mM UDP-[14C]GlcA (3×105 d.p.m.), 100 mM Mes (pH 6.5), 10 mM MnCl2 and 10 μl of the resuspended beads. The mixtures were incubated at 37 °C overnight. The products of the polymerization reactions were isolated by gel filtration on a Superdex™ 75 column with 0.25 M NH4HCO3/0.7% propan-1-ol as the eluent.
Expression of the soluble forms of recombinant C4ST-1 and C4ST-2 and identification of reaction products
Each expression plasmid (6.0 μg) was transfected into COS-1 cells on 100-mm-diameter plates using FuGENE® 6 according to the manufacturer's instructions and as described previously . At 2 days after transfection, 1 ml of the culture medium was collected and incubated with 10 μl of IgG–Sepharose for 1 h at 4 °C. The beads recovered by centrifugation were washed with and then resuspended in the assay buffer, and tested for sulfotransferase activity. Assays for sulfotransferase were described previously  with slight modifications. Briefly, the standard reaction mixture (30 μl) contained 10 μl of resuspended beads, 50 mM imidazole/HCl (pH 6.8), 2 mM dithiothreitol, 10 μM [35S]PAPS (3×105 d.p.m.), and 1 nmol of Oligo-3 or Oligo-4 as an acceptor substrate respectively. The reaction mixtures were incubated at 37 °C overnight and gel-filtered using a syringe column packed with Sephadex G-25 (superfine) . The radioactive fractions containing the enzyme reaction products were pooled and desiccated. The isolated reaction product was digested with chondroitinase AC-II. The products of enzymatic digestion were analysed using the Superdex™ peptide column with 0.25 M NH4HCO3/0.7% propan-1-ol as the eluent.
Introduction of ChGn-1 or ChGn-2 into sog9 and L cells
To examine whether ChGn-1 or/and ChGn-2 collaborates with C4ST-1 to regulate the length of CS chains, overexpression of ChGn-1 or ChGn-2 in L and sog9 cells was carried out. A pCMV-Script expression vector harbouring the open reading frame of human ChGn-1 or ChGn-2 was transfected into sog9 or L cells, and the neomycin analogue G418 was used to select transfected cells. Each of the resultant transfected colonies was picked and propagated for experiments, and the expression of ChGn-1 or ChGn-2 in the cells was measured by quantitative real-time RT–PCR. As shown in Tables 2 and 3, the composition of the disaccharides and the amount of CS isolated from the stable clones, designated L-ChGn-1, L-ChGn-2, sog9-ChGn-1 and sog9-ChGn-2 cells, were determined by HPLC. Whereas the disaccharide compositions in L-ChGn-1 and L-ChGn-2 cells were similar to those in control L cells, the amount of CS was greater in L-ChGn-1 and L-ChGn-2 cells than in the controls (Table 2). Although the proportion of ΔDi-4S [ΔHexAα1-3GalNAc(4S)] units and the total amount of CS was higher in sog9-ChGn-1 than in controls, the proportion of the ΔDi-4S subunits and the amount of CS in sog9-ChGn-2 cells was similar to that in control sog9 cells (Table 3). These results indicated that overexpression of ChGn-2 increased the amounts of CS in L cells, but not in sog9 cells, and that ChGn-2 can regulate the amount of CS only in the presence of C4ST-1.
Prompted by these observations, we next examined whether knockdown of ChGn-2 decreases the amount of CS in L cells. The efficiency of gene silencing was determined by quantitative real-time RT–PCR. As shown in Table 2, transfection of ChGn-2 shRNA (L-shRNA ChGn-2-1 and L-shRNA ChGn-2-2 cells: two different shRNAs directed against ChGn-2 were used) resulted in a 50 or 80% knockdown of ChGn-2 mRNA and a 7 or 26% decrease in the amount of CS when compared with control L cells. These findings indicated that knockdown of ChGn-2 decreased the amounts of CS in L cells, corresponding to the expression levels of ChGn-2 (Table 2). Therefore ChGn-2 can regulate the amount of CS, and the amount of CS is proportional to ChGn-2 expression levels.
Involvement of ChGn-2 in CS chain elongation
We next compared the length of CS chains obtained from L-ChGn-2-1, L-shRNA ChGn-2-2, sog9-ChGn-2-1, and mock-transfected L and sog9 cells. Gel-filtration analysis using a Superdex™ 200 column revealed that CS chains in L-ChGn-2-1 cells were much longer than in control L cells, whereas CS chains in L-shRNA ChGn-2-2 cells were markedly shorter than in control L cells (Figure 2A). In contrast, CS chains in sog9-ChGn-2-1 cells were shorter than in mock-transfected cells (Figure 2B). These results indicated that the expression of ChGn-2 in the presence of C4ST-1 resulted in longer and more abundant CS chains. In addition, in the absence of C4ST-1, ChGn-2 did not regulate CS chain length. Notably, the length of CS chains in L-shRNA ChGn-2-2 cells was comparable with that in sog9 cells (Figures 2A and 2B), suggesting that ChGn-2 and C4ST-1 have non-redundant functions in the chain elongation of CS and that the two enzymes co-operate to elongate CS chains.
Contribution of enzyme activity of ChGn-2 or C4ST-1 in CS biosynthesis
To determine whether N-acetylgalactosaminyltransferase activity of ChGn-2 contributed to chain elongation, we constructed a ChGn-2 mutant that lacked enzymatic activity. On the basis of the sequence alignment of ChSy family members, ChGn-2 has only one putative DXD motif, DVD (Asp367-Val-Asp369), and DXD motifs are responsible for UDP–sugar binding in many glycosyltransferases . It was therefore expected that the ChGn-2 D367A (AVD) mutant would not have N-acetylgalactosaminyltransferase activity. To confirm the expression and activity of ChGn-2 D367A, the soluble mutant was generated by replacing the first 36 amino acids of ChGn-2 D367A with a cleavable insulin signal sequence and the Protein A IgG-binding domain, as described previously . The soluble mutant protein was expressed and evaluated for N-acetylgalactosaminyltransferase activity; as expected, no such activity was detected. We then investigated whether overexpression of ChGn-2 D367A increased the amount of CS in L cells. As shown in Table 2, the amount and disaccharide composition of CS isolated from each of the representative stable clones were similar to control L cells. These results indicated that the N-acetylgalactosaminyltransferase activity of ChGn-2 played an essential role in increasing CS levels.
Next, to verify that the sulfotransferase activity of C4ST-1 contributed to CS chain elongation, the C4ST-1 mutant, which lacks sulfotransferase activity, was overexpressed in sog9 cells. The mutated form of C4ST-1 (C4ST-1 R186A), which fails to bind PAPS, was described previously . The disaccharide composition and the amount of CS in C4ST-1 R186A cells were analysed by HPLC (Table 3). The amount of CS and the disaccharide composition in sog9-C4ST-1 R186A cells were similar to those in control sog9 cells (Table 3).
We next compared the length of CS chains obtained from sog9-C4ST-1-1 , sog9-C4ST-1 R186A-1 and mock-transfected sog9 cells. Gel-filtration analysis using a Superdex™ 200 column revealed that CS chains in sog9-C4ST-1-1 cells were longer than those in sog9-C4ST-1 R186A-1 or control sog9 cells (Figure 2C). The mean molecular masses were 101 (sog9-C4ST-1-1), 78 (sog9-C4ST-1 R186A-1) and 79 kDa (control sog9 cells) respectively (Figure 2C). Notably, the length of CS chains in sog9-C4ST-1 R186A-1 was comparable with that in sog9 cells (Figure 2C). These findings indicated that CS levels were not rescued by introduction of the mutated C4ST-1 R186A; therefore the enzymatic activity of both ChGn-2 and C4ST-1 was necessary to regulate the amount and chain length of CS.
Involvement of non-reducing terminal GalNAc(4S) structure in chondroitin polymerization
We predicted that the non-reducing terminal 4-O-sulfation of GalNAc residues that are newly synthesized by C4ST-1 and ChGn-2 may facilitate the elongation of CS chains by the chondroitin polymerases that synthesize the CS backbone. Previously, we demonstrated that chondroitin polymerization occurred when any two of ChSy-1, ChSy-2, ChSy-3 and ChPF were co-expressed [8–10] (see Figure 1). Hence, polymerization activity was measured using Oligo-1, -2, -5 or -6 as acceptor substrates and ChSy-1 co-expressed with ChPF as the initial enzyme source. Each reaction product obtained with Oligo-1, -2, -5 or -6 was analysed by gel-filtration chromatography using a Superdex™ 75 column, as shown in Figure 3(A). The chondroitin chains synthesized on Oligo-5 were much longer than those synthesized on Oligo-1, -2 or -6. In contrast, no polymerization was induced on these acceptor oligosaccharides when co-expressed ChSy-1 and ChSy-2, ChSy-1 and ChSy-3, ChSy-2 and ChSy-3, ChSy-2 and ChPF, or ChSy-3 and ChPF were used (see Supplementary Figure S1 and Supplementary Table S1 at http://www.BiochemJ.org/bj/434/bj4340321add.htm). Interestingly, although ChSy-1 and ChPF mRNA were expressed in both L and sog9 cells, ChSy-2 and ChSy-3 mRNA were hardly expressed in these cell lines (see Supplementary Figure S2 at http://www.BiochemJ.org/bj/434/bj4340321add.htm). These results indicated that chondroitin polymerization by the ChSy-1/ChPF enzyme complex was facilitated by the non-reducing terminal GalNAc(4S) structure (Figure 3B).
Substrate specificity of C4ST-1 for the non-reducing terminal GalNAc
Previously, it has been reported that C4ST-1 catalyses the transfer of sulfate from PAPS to position 4 of the internal GalNAc residue of chondroitin [18,19]; however, it is not clear whether C4ST-1 is also responsible for transferring the sulfate to position 4 of the non-reducing terminal GalNAc residue. Hence, we examined the sulfotransferase activity of C4ST-1 at a non-reducing terminal GalNAc residue. However, C4ST-1 did not use the trisaccharide GalNAcβ1-4GlcAβ1-3GalNAc as a substrate. Then, the sulfotransferase activity was determined using longer oligosaccharides such as Oligo-3 or -4 as the acceptor substrates and [35S]PAPS as the donor substrate. The 35S-labelled products were digested exhaustively with chondroitinase AC-II, which cleaves the β1-4-N-acetylgalactosaminidic linkage; two radioactive peaks were detected at the GalNAc-4-O-SO4 and ΔDi-4S positions in 1:10 (Figure 4A for Oligo-3, ○) or 1:6 molar ratios (Figure 4B for Oligo-4, ○) respectively. In sharp contrast, C4ST-2 transferred the sulfate only to the internal GalNAc residues (Figures 4A and 4B, ●). These results indicated that C4ST-1 transferred the sulfate from PAPS to the non-reducing terminal GalNAc residue and to the internal GalNAc residues (Figure 4C). Thus 4-O-sulfation of the non-reducing terminal structure of CS chains by C4ST-1 facilitated the elongation of CS chains by chondroitin polymerases that synthesize the CS backbone.
Previously, we demonstrated that sog9 cells, a murine L cell mutant, were deficient in C4ST-1 and synthesized shorter CS chains . The transfection of C4ST-1 into sog9 cells resulted in a recovery in the amount of CS and an increase in the length of the CS chains; moreover, the expression level of C4ST-1 correlated well with the recovery of 4-O-sulfated CS levels . In addition, C4ST-1-deficient mice showed a 90% decrease in GalNAc(4S) structures as well as a severe reduction in the amount of CS . Although these results suggested that C4ST-1 regulates not only 4-O-sulfation of CS, but also the amounts and length of CS chains, the C4ST-1 mechanism was not clear because C4ST-1 is only responsible for the sulfation of the 4-O-position of GalNAc residues in CS chains. In the present study, we showed that C4ST-1 co-operates with ChGn-2 in chain elongation of CS moieties (Figure 5). Overexpression of ChGn-2 increased the amount and chain length of CS in L cells, but not in sog9 cells (Tables 2 and 3). Knockdown of ChGn-2 decreased the amount of CS in L cells in a manner relative to ChGn-2 expression levels (Table 2). Additionally, the amount of CS was not increased by the introduction of mutated C4ST-1 or ChGn-2, both of which lacked enzyme activity. Furthermore, the non-reducing terminal 4-O-sulfation of GalNAc residues facilitated the elongation of CS chains through chondroitin polymerase consisting of ChSy-1 and ChPF (Figures 3 and 5). Notably, the similar tissue distribution profiles of ChGn-2 and C4ST-1 suggest further that these enzymes co-operate in the synthesis of CS moieties [13–15,18].
In a previous study, in vitro chondroitin polymerization was demonstrated when α-thrombomodulin, which contains a truncated GAG–protein linkage region tetrasaccharide sequence, was used as an acceptor with the co-expression of any two of ChSy-1, ChSy-2, ChSy-3 and ChPF as enzyme sources [8–10]. The findings indicate that ChGn-1 and ChGn-2 [11–14], which harbour both GalNAcT-I and -II activities, are dispensable for chondroitin polymerization at the linkage region tetrasaccharide sequence. However, the present study demonstrated that overexpression of ChGn-2 increased CS amounts and chain lengths, but overexpression of a mutated ChGn-2 lacking enzymatic activity failed to increase the amount of CS in L cells. Thus ChGn-2 was involved in the chain-elongation mechanism of CS, and its enzymatic function played an important role in this chain elongation.
In contrast, overexpression of ChGn-1 in sog9 cells increased the total amount of CS and the proportion of ΔDi-4S units compared with that in controls and in sog9 cells overexpressing ChGn-2 (Table 3). These results suggested that the function of ChGn-1 was different from that of ChGn-2. Previously, it was revealed that C4ST-1 mRNA is not expressed in sog9 cells, whereas C4ST-2 and D4ST-1 mRNA are expressed . Thus ChGn-1 regulation of the amount of CS through its co-operation with C4ST-2 and/or D4ST-1 was expected. Comparative analysis of ChGn-1-  and ChGn-2-knockout mice would provide further insight into the distinct functions of these genes.
In Caenorhabditis elegans and Drosophila melanogaster, CS is synthesized as non-sulfated chondroitin and 4-O-sulf-ated CS respectively [34,35]. Additionally, in C. elegans, there is a single orthologue for each of ChSy and ChPF, but none for ChGn-1 or -2, despite the existence of chondroitin in the nematode . In fact, the ChSy and ChPF orthologues are sufficient to synthesize chondroitin, and the system for chondroitin biosynthesis in C. elegans seems to be simpler than those in D. melanogaster and mammals . On the other hand, there is a single orthologue for each of ChSy, ChPF and ChGn in D. melanogaster. Our group showed previously that the mean chain length of chondroitin in C. elegans is short (~40 kDa) and that of CS in D. melanogaster is ~70 kDa [34,35]. These results, together with those of the present study, strongly suggested that the GalNAc-4-O-sulfation of CS chains by C4ST and ChGn facilitated the elongation of CS chains by a chondroitin polymerase (e.g. the ChSy–ChPF complex) which is involved in synthesizing the CS backbone. Hence, we predicted that the diverse size of CS chains per core protein is strictly regulated not only by chondroitin polymerase, but also by CS sulfotransferases and N-acetylgalactosaminyltransferases. In addition, we suggest that these mechanisms are highly conserved through evolution.
Earlier studies have indicated that the sulfation of GAG chains ordinarily occurs in conjunction with polymerization at a single Golgi site and that there appears to be close interrelationships between sulfation and polymer elongation/termination . In fact, our previous findings revealed that specific sulfate groups have either stimulatory or inhibitory effects on GalNAc transfer, and, consequently, sulfation reactions indeed play important roles in chain elongation and termination [29,39]. In addition, we reveal in the present study that the non-reducing terminal 4-O-sulfation of GalNAc residues synthesized by C4ST-1 and ChGn-2 facilitated the elongation of CS chains through chondroitin polymerase consisting of ChSy-1 and ChPF (Figures 3 and 5). In this regard, it should be noted that there is a progressive decrease in 4-sulfation to 4,6-disulfation of GalNAc residues on the non-reducing terminal residues of CS in human cartilage during development . Moreover, the CS chains on aggrecan isolated from human cartilage become shorter with age ; therefore we suggest that the prior specific sulfation patterns in growing CS chains profoundly affected chain elongation and termination.
Previously, it was demonstrated that human lung fibroblasts treated with TGFβ (transforming growth factor β) alone or in combination with EGF (epidermal growth factor) and PDGF (platelet-derived growth factor) increased the production of CS PG and the activity of C4ST-1 . In addition, it was reported that TGFβ or PDGF treatment of arterial smooth muscle cells results in the elongation of CS chains [3,42,43]. CS elongation is reported to be associated with increased binding of atherogenic lipids and atherosclerosis progression . We demonstrated that C4ST-1 regulated the chain length and amount of CS in co-operation with ChGn-2; therefore these mitogens might promote the elongation of CS by controlling the expression of relevant enzymes, such as C4ST-1 and ChGn-2. Thus understanding the mechanisms that regulate the expression of C4ST-1 and ChGn-2 during atherosclerosis progression may lead to the identification of potential therapeutic targets for intervention in the pathological process of atherosclerosis.
Tomomi Izumikawa, Yuka Okuura, Toshiyasu Koike and Naoki Sakoda performed the research; Hiroshi Kitagawa designed the research; Tomomi Izumikawa, Yuka Okuura and Hiroshi Kitagawa analysed the data; and Tomomi Izumikawa and Hiroshi Kitagawa wrote the paper.
This work was supported in part by the Science Research Promotion Fund of the Japan Private School Promotion Foundation, Health Sciences Research Grant on Psychiatric and Neurological Diseases and Mental Health [grant number H21-012] from the Ministry of Health, Labour and Welfare of Japan, and Grants-in-aid for Scientific Research-B [grant number 21390025 (to H.K.)] from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.
We are especially grateful to Professor Frank Tufaro for kindly providing the sog9 cells. We also thank Dr Toru Uyama for valuable discussion, and Yuuki Tamaki for technical assistance.
Abbreviations: C4ST, chondroitin 4-O-sulfotransferase; C6ST-1, chondroitin 6-O-sulfotransferase-1; ChGn, chondroitin N-acetylgalactosaminyltransferase; ChPF, chondroitin-polymerizing factor; ChSy, chondroitin synthase; CS, chondroitin sulfate; D4ST, dermatan 4-O-sulfotransferase; GAG, glycosaminoglycan; GalNAc4S-6ST, N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase; GalNAcT, β1,4-N-acetylgalactosaminyltransferase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PAPS, adenosine 3′-phosphate 5′-phosphosulfate; PDGF, platelet-derived growth factor; PG, proteoglycan; RT, reverse transcription; shRNA, short hairpin RNA; TGFβ, transforming growth factor β
- © The Authors Journal compilation © 2011 Biochemical Society